Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Can anyone explain what's going on ?Looking on Bidstats it shows that Tanner Pharma UK were awarded a further six months contract on 20/03/23 to supply lateral flow tests.
https://bidstats.uk/tenders/2023/W07/792723523
Then seventeen days later documents at companies house show the company was served with a compulsory strike off notice.From what information is available at companies house they don't appear to have filed any accounts since those for 2020. Finally on the 24/03/23 the compulsory strike off notice has now been discontinued. ?????????
https://find-and-update-company-information.service.gov.uk/company/09566234
Well one things for sure Bob Enck must see an opportunity to make money with Proton DX, whether this helps Novacyts cause remains to be seen. It's well doing some research into his background, especially the story about the gold bullion his other company bought last year on behalf of investors.
We were told last September that the Clonit assays for respiratory, gastric and st infections would be fully validated for use with the Q instruments and launched in Q1 2023 .They also said that some of their own r+d assays would start to come through the regulatory process in 12 months time ,which takes us to this April. They can't keep stum much longer.
I also found this article from last summer regarding the Proton DX test platform that Katalyst are starting to market. In it Proton DX mention that they have signed a deal with an undisclosed partner and that there are two more in the pipeline . They also added that they are developing a next generation test which removes the need for rna extraction before running the test .This is field that Novacyt have experience with, having developed the Exig direct and Promate chemistry. Bit of a long shot ,but could Novacyt be helping them with this .
https://www.genomeweb.com/molecular-diagnostics/imperial-college-spinout-protondx-plans-commercialization-rapid-molecular-dx
A short video explaining some of the work that the BIVDA do for companies who are members. I also see that Katalyst who Novacyt deal with are members, plus their new partner Proton DX.
https://youtu.be/rWweZ7Os4o
The UK gov published a policy paper relating to the Medical Technology Strategy earlier this month. This covers a wide range of equipment, diagnostics and more that are used by the NHS. Quite a long read with plenty said about engagement between the NHS and industry on what they require . This all counts for nothing if the government then favours a cheap, foreign supplier instead.
https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy
Try again
https://www.linkedin.com/in/christopher-rongo-a1447132
Hi Larry, Jason Venn the co-founder of Veon used to be on the LinkedIn page of professor Christopher Rongo (Rutgers University). For some reason it was removed shortly after I mentioned it on this board.
https://www.linkedin.com/in/christopher-rongo-91447132
Mehul Vora now of Novacyt completed a lot of research work at Rutgers with Chris Rongo, but there's no indication if they are still collaborating on anything.
Hi Kaeren, you mentioned Novacyts relationship with Southampton University the other day. Several of the staff have developed a biosensor platform for the rapid screening of bacteria in patient samples. They have formed a spin off company ( ifast diagnostics) which was incorporated last April.In November they raised nearly £2 million to further the project and aim to have platforms available for research this year and a full launch in 2024. There is a wealth of talented research at the uni that could be tapped into, but at the moment there is no clear picture what Novacyt are doing.
https://ukinnovationscienceseedfund.co.uk/ifast-diagnostics-raise-2m-to-track-and-treat-antibiotic-resistant-bugs/
A little information on R+D expenditure over the last three years
2020- H1 £593,000. H2 £1,037,000 Total £1,630,000
2021- H1 £1,875,000. H2 £2,940,000 Total £4,815,000
2022- H1 £3,271,000. H2 ?? ??
I would expect the spend for H2 2022 to be higher than H1 as the development work on several tests wasn't announced until April . They also stated last April that some of the new tests that were at a more advanced stage should be ready for commercialization in 12 months. It would be good to know if they are still on track with this, because at the moment they have got silence with all aspects of the business down to a fine art.
KT, if Alltests Biotech are the actual manufacturer it would appear that Novacyt have partnered with a Chinese company for the LT reader.
https://www.alltests.com.cn/Mobile/Productinfo/517
Hi Neil, from what I can see there is a brand new unit 1b up for lease.
https://watchmoorpoint.co.uk/